Physician profile
Ronald Powell
NPI 1164405965
$7,965.93
in general payments reported to CMS, 2019-2025
28 companies · $1,818 in 2025
The $1,818 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $423 · 2021: $1,119 · 2022: $1,267 · 2023: $1,229 · 2024: $1,393 · 2025: $1,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,440.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,283.36 | 2019-2025 | |
| Janssen Biotech, INC. | $1,763.11 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $744.87 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Ironwood Pharmaceuticals, INC | $674.69 | 2019-2024 | Linzess |
| Pfizer INC. | $367.40 | 2019-2025 | |
| Genzyme Corporation | $294.10 | 2022-2025 | |
| Gilead Sciences, INC. | $224.14 | 2019-2025 | |
| Madrigal Pharmaceuticals | $202.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.12 | 2019-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $174.13 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $151.52 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $139.90 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $133.54 | 2019-2024 | Dificid |
| Lilly USA, LLC | $130.65 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $80.11 | 2023-2025 | Rebyota, Cimzia |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $62.46 | 2022-2023 | |
| Celgene Corporation | $46.59 | 2023-2024 | Zeposia |
| Amgen INC. | $43.87 | 2020-2022 | |
| Ardelyx, INC. | $43.80 | 2025 | Ibsrela |
| Braintree Laboratories, INC. | $36.89 | 2024-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $34.75 | 2019-2023 | Ocaliva |
| Qol Medical, LLC | $29.34 | 2022 | |
| Allergan, INC. | $24.43 | 2019 | |
| Exact Sciences Corporation | $17.86 | 2025 | The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $17.31 | 2023 | Givlaari |
| Daiichi Sankyo INC. | $15.78 | 2020 | |
| Novo Nordisk INC | $15.19 | 2025 | Wegovy |
| Shire North American Group INC | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.